Trials / Terminated
TerminatedNCT01050283
A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144)
A Multicenter Trial to Evaluate 18F-FDG Uptake by PET in Patients With Advanced Pancreatic Adenocarcinoma as an Early Indicator of Drug Activity
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 35 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine whether \[18F\]-fluorodeoxyglucose-positron emission tomography (FDG-PET) can be used to screen for the activity of novel pancreatic cancer treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Comparator: [18F]-FDG PET/CT and Volumetric CT | Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2012-05-01
- Completion
- 2012-05-01
- First posted
- 2010-01-15
- Last updated
- 2015-07-27
Source: ClinicalTrials.gov record NCT01050283. Inclusion in this directory is not an endorsement.